Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Chemoradiotherapy for Advanced ESCC
NCT06138028Phase 3Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Started Sep 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06138028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138028.